Contineum Therapeutics
CTNM
52 hedge funds and large institutions have $258M invested in Contineum Therapeutics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 16 increasing their positions, 16 reducing their positions, and 5 closing their positions.
60% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 5
13% more capital invested
Capital invested by funds: $229M → $258M (+$29.2M)
6% more funds holding
Funds holding: 49 → 52 (+3)
3.67% more ownership
Funds ownership: 68.54% → 72.22% (+3.7%)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$15.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$7.16M |
| 3 |
Squarepoint
New York
|
+$3.83M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$831K |
| 5 |
State Street
Boston,
Massachusetts
|
+$417K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Suvretta Capital Management
New York
|
-$6.39M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.25M |
| 3 |
Adage Capital Partners
Boston,
Massachusetts
|
-$1.82M |
| 4 |
ACM
Altium Capital Management
New York
|
-$1.15M |
| 5 |
PA
Perceptive Advisors
New York
|
-$959K |
CTNM Hedge Fund Activity: Q3 2024 in Review
52 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Contineum Therapeutics (CTNM) for Q3 2024, worth a combined $258M — up 13% from $229M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new CTNM positions and 5 closed out — a net gain of 3 holders — while 16 added to existing stakes and 16 trimmed.
The largest buyer was Franklin Resources, adding an estimated $15.7M. The largest seller was Suvretta Capital Management, cutting an estimated $6.39M.
- 52 institutional investors held Contineum Therapeutics (CTNM) as of Q3 2024, up from 49 in Q2 2024.
- Funds reported $258M of Contineum Therapeutics stock for Q3 2024, up 13% quarter-over-quarter.
- 8 funds opened new Contineum Therapeutics positions in Q3 2024 and 5 closed out, a net change of +3 holders.
- The largest Contineum Therapeutics buyer in Q3 2024 was Franklin Resources, an estimated $15.7M added.
- The largest Contineum Therapeutics seller in Q3 2024 was Suvretta Capital Management, an estimated $6.39M sold.
Based on aggregated 13F filings for Q3 2024.